Results 121 to 130 of about 6,410,919 (241)

Redox-responsive carrier-free nanoassemblies enable dual topoisomerase I/II inhibition for metastasis-suppressed breast cancer therapy

Biomedical Technology
Background: Breast cancer remains a critical unmet clinical challenge due to its aggressive metastasis behavior and limited treatment options. Topoisomerase inhibitors are widely available clinically but fail to address the compensatory upregulation of ...
Jingyi Jiao, Feng Gao, Ziqi Dai, Shuhe Jia, Zixuan Zhang, Yixuan Lin, Zhuo Cao, Yongji Liu, Quanlin Yu, Tianzhen Liang, Chenze Zhang, Bing Xu, Haimin Lei   +12 more
doaj   +1 more source

Harnessing the Folding of Antitumor Peptides for Controlled Carrier‐Free Drug Delivery

Small, EarlyView.
A disulfide‐bridged stapled p53 α‐helix co‐assembled with doxorubicin into protease‐resistant nanocomplexes. Reductive intracellular conditions induced helix refolding and nanostructure disassembly, which enabled the coordinated release of the chemotherapeutic agent and anticancer peptide.
Jae Yun Lee, Moo Chang Park, Sung Chan Choi, Jieun Kim, Joo‐young Kim, Jiah Lee, Hyun Jin Kim, Kyobum Kim, Yongju Kim, Woo‐jin Jeong   +9 more
wiley   +1 more source

Therapy-related acute leukemia associated with involvement of 11q23 after high grade non-Hodgkin lymphoma

Haematologica, 1998
Therapy-related acute myeloid leukemias with balanced translocations affecting the 11q23 chromosome region are one of the most serious complications of treatments with topoisomerase II inhibitor drugs as epipodophillotoxins and anthracyclines.
G Martinelli, N Testoni, PL Zinzani, A Biondi, G Cimino, S Tura   +5 more
doaj  

HER2‐Targeted AIE Nanotheranostics Overcome SHR‐A1811 Resistance via Immunogenic Pyroptosis and Tumor‐Associated Macrophage Reprogramming in Breast Cancer

Small, EarlyView.
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu, Nisha Wu, Zaihui Peng, Guozhi Zhang, Lin Ren, Qiuyun Li, Jie Xiao, Jing He, Yuxiuzi Xiao, Li Ma, Yi Zhang, Ying Gong, Xiaowei Qi   +12 more
wiley   +1 more source

A lysosome‐targeted ultra‐sensitive viscosity probe for monitoring viscosity alterations during chemotherapy

Smart Molecules, EarlyView.
A novel chemosensing platform based on a molecular rotor architecture is established for specific, dynamic detection of lysosomal viscosity. The platform allows real‐time tracking of lysosomal viscosity fluctuations induced by various chemotherapeutic agents, highlighting its significant potential as a powerful tool for early cancer diagnostics and ...
Haoyang Song, Hui Bian, Lei Liu, Gahyeon Park, Bingqing Sun, Qiongzheng Hu, Juyoung Yoon   +6 more
wiley   +1 more source

Resistomycin as a DNA-targeted topoisomerase II inhibitor: Computational and mechanistic insights into its anticancer potential

Journal of Chemical Research
Resistomycin, a microbial secondary metabolite, exhibits promising anticancer potential, yet its mechanism of action remains poorly understood. Here, we combined computational and biological assays to investigate its activity against Topoisomerase II ...
Mohamed S Abdelfattah, Ibrahim H Eissa, Ahmad E Mostafa, Eslam B Elkaeed, Aisha A Alsfouk, Abdulla A Mahmoud, Ibrahim M Ibrahim, Ahmed M Metwaly   +7 more
doaj   +1 more source

Deciphering diverse cell‐death patterns to predict the prognosis and potential therapy target of hepatocellular carcinoma patients

VIEW, EarlyView.
Abstract Ninety percent of all primary liver malignancies are hepatocellular carcinomas (HCC), making liver cancer the third most common cause of cancer‐associated mortality. Different patterns of programmed cell death (PCD) are crucial for the survival of tumors, and they might serve as a prognostic marker for HCC.
Lin Ding, Qian Li, Wenjing Yang, Te Liu, Tongtong Tian, Yu Liu, Chunyan Zhang, Baishen Pan, Beili Wang, Fan Wu, Wei Guo   +10 more
wiley   +1 more source

cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. [PDF]

J Clin Invest, 2019
Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P, Huang P, Chen S, Li W, Xia LP, Xia X.   +15 more
europepmc   +1 more source

Aclacinomycin A stabilizes topoisomerase I covalent complexes.

, 1997
International audienceAclacinomycin A (aclarubicin) is an anthracycline anticancer agent with demonstrated activity against both leukemias and solid tumors.
Nitiss, J, Pommier, Y, Pourquier, P.
core   +1 more source

Diffuse Skin Sclerosis in a Patient With Lung Cancer

JEADV Clinical Practice, EarlyView.
Anna‐Sophia Leven, Eva Hadaschik, Alpaslan Tasdogan   +2 more
wiley   +1 more source